Royalty Pharma
RPRX
RPRX
235 hedge funds and large institutions have $10.3B invested in Royalty Pharma in 2021 Q2 according to their latest regulatory filings, with 56 funds opening new positions, 91 increasing their positions, 57 reducing their positions, and 32 closing their positions.
Holders
235
Holders Change
+23
Holders Change %
+10.85%
% of All Funds
4.1%
Holding in Top 10
9
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-18.18%
% of All Funds
0.16%
New
56
Increased
91
Reduced
57
Closed
32
Calls
$34.6M
Puts
$48M
Net Calls
-$13.4M
Net Calls Change
-$14.3M
Top Buyers
| 1 |
1
Amundi
Paris,
France
|
$116M |
| 2 |
2
Morgan Stanley
New York
|
$2.08B |
| 3 |
3
Janus Henderson Group
London,
United Kingdom
|
$154M |
| 4 |
4
Aberdeen Group
Edinburgh,
United Kingdom
|
$77.2M |
| 5 |
5
Vanguard Group
Malvern,
Pennsylvania
|
$998M |
